Philip James Wealth Mangement LLC Has $8.50 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Philip James Wealth Mangement LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 8.3% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 320,431 shares of the biopharmaceutical company’s stock after selling 28,866 shares during the period. Pfizer makes up about 1.1% of Philip James Wealth Mangement LLC’s holdings, making the stock its 15th largest holding. Philip James Wealth Mangement LLC’s holdings in Pfizer were worth $8,501,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of PFE. Creative Planning increased its position in Pfizer by 17.1% during the third quarter. Creative Planning now owns 1,820,731 shares of the biopharmaceutical company’s stock worth $52,692,000 after acquiring an additional 266,167 shares during the period. Swedbank AB increased its position in Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after acquiring an additional 37,636 shares during the period. Stratos Wealth Partners LTD. increased its position in Pfizer by 11.6% during the third quarter. Stratos Wealth Partners LTD. now owns 290,370 shares of the biopharmaceutical company’s stock worth $8,403,000 after acquiring an additional 30,107 shares during the period. Stratos Wealth Advisors LLC increased its position in Pfizer by 0.6% during the third quarter. Stratos Wealth Advisors LLC now owns 111,559 shares of the biopharmaceutical company’s stock worth $3,229,000 after acquiring an additional 621 shares during the period. Finally, Stratos Investment Management LLC increased its position in Pfizer by 15.6% during the third quarter. Stratos Investment Management LLC now owns 14,928 shares of the biopharmaceutical company’s stock worth $432,000 after acquiring an additional 2,013 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 0.6 %

Shares of NYSE PFE opened at $25.50 on Monday. The firm’s 50-day simple moving average is $26.28 and its 200 day simple moving average is $27.56. The company has a market cap of $144.48 billion, a price-to-earnings ratio of 18.08, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.75%. Pfizer’s dividend payout ratio is 121.99%.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research reports. Citigroup dropped their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. UBS Group lowered their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Wolfe Research began coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.